From time to time IDSC directors will publish a whitepaper for the benefit of our clients. Past authors include Jeff Simpson and Dr. Lauren Castalini. Jeff published a whitepaper on "Commercial Assessment & Due Diligence" and Lauren published a whitepaper on "Nutraceuticals and Focus on Medical Foods." You can read about Jeff and Lauren in their Bios below or on the Bios page.
ß ß ß Click on the menu buttons to the left to view Jeff and Lauren's whitepapers.
In addition to IDSC's white paper series, IDSC's directors are often invited to present papers at national conferences. When relevent to our clients, we will post those papers on this page for for your benefit. We have posted John Domagala's "Where are all the Antibacterials?," Dave Moreland's "Some Thoughts on Analyzing Long Molecular Dynamics Trajectories," and Mark Creswell's "Outsourcing Medicinal Chemistry for the Beginner adn Advanced Outsourcing Manager."
IDSC's next whitepaper will be authored by Francie Kivel, and will be on the topic of Stem Cell Therapy. Francie will briefly give some of recent groundbreaking technology while discussing briefly how to navegate the very newly charted regulatory path to approval and marketing of a new stem cell therapy. You can see Francie's Bio by clicking here.
Lauren Costantini is an advisor to emerging life science and medical technology companies. She has 20+ years developing therapeutics for several indications, with an emphasis on neurodegenerative diseases. Her experience includes leading products from research through clinical, regulatory, and commercialization stages. She also plays a key role connecting her early-stage companies with potential partners, venture capital, and angel investors, as well as directing due diligence for in- and out-licensing activities. She is currently Vice President of Therapeutics and Device Development for CID4, and holds board seats in several companies and non-profits. Previously she was Vice President at Accera where her team developed and launched an Alzheimer's therapeutic, she was on faculty at Harvard Medical School, and was voted "Business Advisor of the Year" 2011 by U Colorado TTO.
Over 30 years of infectious disease experience in Warner-Lambert/Pfizer with broad based training in medicinal chemistry, management, building program portfolios, and attrition analysis. Managerial experience included 8 years supervision of research teams (4-14 colleagues) and 7 years of TA leadership (30- over 100 colleagues at two sites) with full responsibilities for TA chemistry and biology strategy, product profiles, patents, publications, product development, and in licensing. Brought 30 compounds into full development with 8 compounds reaching the clinic. Medicinal chemistry experience included bringing leads from HTS to full development. Product development experience included in depth understanding of market needs and trends, as well as all aspects of preclinical safety and PK assessments.
A skilled marketing and sales executive with proven accomplishments at The Upjohn Company, Pharmacia and Pfizer, Jeff advises biotech and pharmaceutical companies on business development, commercialization strategies, product assessments and valuations, portfolio planning, lifecycle planning, advisory boards, competitive intelligence, and launch planning for new products, indications and formulations, for both the US and non-US markets. During his 29 years in the pharmaceutical industry, Jeff's commercialization experience includes products for psychiatry, neurology, pain management, sleep disorders, womens health, infectious diseases, inflammation, metabolic diseases, urology, immunology, and dermatology.
Dr. Moreland has over 21 years of research experience in a large pharmaceutical company and an additional 7 years of consulting experience working with biotech, academic, and large pharma clients. With broad expertise in molecular modeling, cheminformatics/QSAR, and structural bioinformatics, he has made key contributions to projects in several therapeutic areas, including CNS, cardiovascular, antiretroviral, and antibacterial among others. He has applied both ligand-based and structure-based techniques to help teams identify numerous early clinical candidates, including a phase II compound. He has worked on GPCR, nuclear hormone receptor, protease, and RNA targets, both small molecules and biologics.
If you wish to receive the IDSC White Paper Series, fill out the form below and click "Send." Note that you will also receive IDSC's quarterly newsletter containing current industry scientific articles. However, you can opt out of the newsletter on the form.